Kentera

Oxybutynin, the active ingredient in Kentera, is an antimuscarinic presented as a transdermal patch for transdermal use. It reduces detrusor muscle overactivity, helping manage urinary urgency, frequency, and urge incontinence in adult patients with overactive bladder. By antagonizing muscarinic receptors in the bladder, it diminishes involuntary contractions.

GNH USA supplies Kentera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this prescription‑only urinary antispasmodic. The product complies with EU regulatory standards and is intended for prescription distribution.

Oxybutynin is used to treat conditions related to overactive bladder and urinary urgency. - Overactive bladder: reduces urinary urgency, frequency, and incontinence episodes in adults. - Urge urinary incontinence: decreases the number of leakage episodes caused by involuntary bladder contractions. - Urinary frequency: lowers the number of daytime voids by stabilizing detrusor activity. - Urinary urgency: alleviates sudden, strong urges to void, improving quality of life.

Common Side Effects: - Dry mouth: reduced salivary secretion leading to a feeling of thirst. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary changes in visual focus. - Headache: mild to moderate head discomfort. - Dizziness: sensation of light‑headedness or imbalance. - Urinary retention: difficulty initiating or completing urination.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Tachycardia: unusually fast heart rate. - Angle‑closure glaucoma: sudden eye pain and visual disturbance. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Significant urinary retention leading to overflow incontinence. - Cardiac arrhythmias: irregular heart rhythms requiring medical attention.

Before initiating therapy, consider the following precautions: - Renal or hepatic impairment: adjust monitoring as drug clearance may be affected. - History of urinary retention: evaluate risk of worsening retention. - Narrow‑angle glaucoma: avoid use due to anticholinergic effects on intra‑ocular pressure. - Elderly patients: increased susceptibility to anticholinergic side effects; start with lowest effective dose. - Concomitant anticholinergic medications: assess cumulative anticholinergic burden. - Store at room temperature: keep in original pouch, protect from moisture and heat.

Oxybutynin may interact with other medicines as follows: Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase oxybutynin levels. - Other anticholinergics (e.g., amitriptyline): additive anticholinergic effects. - QT‑prolonging drugs (e.g., quinidine): risk of cardiac arrhythmia. Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin): may reduce oxybutynin effectiveness. - Digoxin: potential increase in serum digoxin concentrations. - Alcohol: may enhance anticholinergic side effects such as dizziness.